Clinical Trial Update: MSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients with Cirrhosis

View source ↗

Summary

Clinical trial evaluating the MSEPT9 biomarker for predicting hepatocellular carcinoma occurrence in patients with cirrhosis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cirrhosis

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Hepatocellular Carcinoma (HCC), Cirrhosis | Status: NOT_YET_RECRUITING